Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells

Florian Hohla, Stefan Buchholz, Andrew V. Schally, Awtar Krishan, Ferenc G. Rick, Luca Szalontay, Andrea Papadia, Gabor Halmos, Frank Koster, Elmar Aigner, Christian Datz, Stephan Seitz

Research output: Contribution to journalArticle

16 Scopus citations

Abstract

The effect of the targeted cytotoxic somatostatin (SST) analog AN-162, consisting of doxorubicin (DOX) conjugated to SST carrier RC-121, was investigated on the growth of human colorectal cancer (CRC) cell lines HT-29, HCT-15, and HCT-116 and a DOX-resistant mouse leukemia cell line P388/R84. mRNA for SST-receptors and high affinity binding sites for SST were detected in all CRC cell lines and in P388/R84 cells. In contrast to DOX alone, AN-162 blocked HCT-116 cells and P388/R84 cells in S/G2 phase and increased the number of apoptotic cells. In vivo, AN-162 reduced the volume of CRC xenografts more effectively than its unconjugated components. Our results suggest that AN-162 inhibits growth of experimental CRC more effectively than DOX and increases sensitivity of DOX resistant human leukemia cells.

Original languageEnglish (US)
Pages (from-to)35-42
Number of pages8
JournalCancer letters
Volume294
Issue number1
DOIs
StatePublished - Aug 1 2010

Keywords

  • AN-162
  • Colon cancer
  • Doxorubicin
  • Somatostatin
  • Targeted therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells'. Together they form a unique fingerprint.

  • Cite this

    Hohla, F., Buchholz, S., Schally, A. V., Krishan, A., Rick, F. G., Szalontay, L., Papadia, A., Halmos, G., Koster, F., Aigner, E., Datz, C., & Seitz, S. (2010). Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells. Cancer letters, 294(1), 35-42. https://doi.org/10.1016/j.canlet.2010.01.018